XTL Biopharma (XTLB) Reports Breakeven Q2 Loss

XTL Biopharma (NASDAQ: XTLB) reported Q2 loss of $0.00, versus $0.00 reported last year.

Following XTL's registered direct offering in April, 2015, XTL had US$4.8 million in cash and cash equivalents as of June 30, 2015.

For earnings history and earnings-related data on XTL Biopharma (XTLB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c